



PRESS RELEASE

FOR IMMEDIATE RELEASE

VALEANT TO ACQUIRE LABORATOIRE DR. RENAUD IN CANADA

Saint-Laurent / Montreal, December 8, 2009 - Valeant Canada has acquired Laboratoire Dr. Renaud, a leading cosmeceutical company located in Laval, Quebec. Laboratoire Dr. Renaud has a state-of-the-art, 45,000 square foot facility that includes a manufacturing plant completed in 2007 specializing in topical formulations. Laboratoire Dr. Renaud currently has annualized sales of approximately \$11 million.

“I believe that our acquisition of Laboratoire Dr. Renaud is a strategic move which permits Valeant Canada to leverage a number of other acquisitions Valeant has made in the area of cosmeceutical dermatology in Australia and in the U.S.” mentioned Mr. Thomas Schlader, President of Valeant Canada.

“This acquisition is part of our continued efforts to build a leading dermatology business by adding respected brand names in our select regions,” said J. Michael Pearson, chairman and chief executive officer, Valeant Pharmaceuticals International. “Laboratoire Dr. Renaud enjoys a high degree of loyalty from esthetic clinics and spas and we believe that Valeant will gain immediate entrée into the cosmeceutical market in Canada. With exclusive access to a world class topical manufacturing plant and a successful sales and marketing infrastructure, we also have the ability to launch select U.S. dermatology products into Canada and further expand our reach in dermatology.”

About Valeant Canada

Valeant Canada is a division of Valeant Pharmaceuticals International (NYSE:VRX). Since 1973, Valeant Canada is specialised in manufacturing, distribution and marketing of pharmaceutical products in neurology, psychiatry, pain management and dermatology.

CONTACT:

Brigitte Carrière
Valeant Canada Limited
514-744-6792
brigitte.carriere@valeant.com

###